NCT03122717 - Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 9, 2017

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2026

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

Gefitinib

gefitinib is a EGFR inhibitor

DRUG

Osimertinib

An orally available, irreversible, third-generation, mutant-selective epidermal growth factor receptor (EGFR) inhibitor

Trial Locations (2)

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston